On the afternoon of October 25, the plenary session of the 2025 International Biomedical Industry Innovation Conference Beijing Forum was held with the theme "Innovation Without Borders, Health for a Shared Future". Yin Li, Secretary of the Beijing Municipal Party Committee, and Lei Haichao, Director of the National Health Commission, delivered speeches. Yin Yong, Deputy Secretary of the Municipal Party Committee and Mayor, attended the event. On the same day, the plan for the BioPark was announced at the conference, aiming to build a global hub for the pharmaceutical and health industry, a primary destination for pharmaceutical talent entrepreneurship, a demonstration zone for artificial intelligence applications, and a pilot zone for pharmaceutical policy reform. Twelve pharmaceutical companies, including Sino Biopharm (1177.HK), will establish a presence in the innovation park to promote the implementation of a batch of key projects. Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, was invited to attend the conference and received a "service package" on behalf of Sino Biopharm. 

Yin Li said in his speech that the Chinese government attaches great importance to medical technology progress and industrial development. The Fourth Plenary Session of the 20th Central Committee of the Communist Party of China has clarified the goals and tasks for China's economic and social development during the "15th Five-Year Plan" period and made deployments for the development of the biopharmaceutical industry. This will surely inject new momentum into international health cooperation. Beijing is a highland for the innovative development of China's biopharmaceutical industry, with rich resources in education, science, technology, and talent, and has established a leading edge in fields such as synthetic biology, cell and gene therapy, and digital health. The pharmaceutical and health industry is full of vitality, with 32 measures to support the high-quality development of innovative medicine launched for two consecutive years, and the industry scale exceeds one trillion yuan. Looking to the future, Beijing will rely on the construction of an international science and technology innovation center to actively build a modern biopharmaceutical industry cluster. We are willing to work with all parties to jointly carry out scientific research to achieve new technological breakthroughs, support close cooperation among universities, research institutes, hospitals and innovative enterprises in Beijing, promote the joint construction and sharing of scientific facilities, pilot platforms and clinical trials, strengthen the application of new technologies such as artificial intelligence, and continuously improve the efficiency of pharmaceutical R&D. We will accelerate the application of innovative achievements to promote new health improvements, make good use of policy advantages such as the pilot zone for securing access to rare disease drugs, optimize the approval and full-process services for innovative drugs, improve the multi-level medical security system, and enhance the accessibility and affordability of products such as vaccines and new drugs. We will strengthen collaboration in the pharmaceutical industry, foster new drivers of development, create a favorable industrial ecosystem, enhance policy support, factor inputs and intellectual property protection, build industrial parks like the BioPark, and promote the optimization and upgrading of the industrial and supply chains. We will deepen international exchanges and cooperation, promote new progress in governance, implement global governance initiatives, strengthen mutual learning in fields such as medical services, public health and healthy aging, enhance the safety management and use of new drugs, new technologies and new equipment, and contribute Beijing's strength to the development of human health. 

Lei Haichao said in his speech that the Fourth Plenary Session of the 20th Central Committee of the Communist Party of China proposed important tasks such as accelerating the construction of a Healthy China and promoting high-quality population development, which will provide broad space, good opportunities, and huge market potential for biopharmaceutical companies to develop in China. Looking to the future, we are willing to work with all parties to adhere to openness and integration, jointly create an open and cooperative innovation environment, expand cooperation space, share innovation resources, solve medical challenges, and work together to improve global health levels. We will adhere to mutual benefit and win-win results, promote the innovative development of the biopharmaceutical industry, and hope that biopharmaceutical companies will increase their investment and R&D innovation in China to jointly cultivate more new technologies, good products, and health promotion solutions for the world. We will improve the coordinated development and governance mechanism of medical services, medical insurance and medicine, strengthen government-enterprise communication, and support the deep integration of technological innovation and industrial innovation. We will adhere to shared development, strive to bridge the global health gap, and share resources and promote development with all parties. 

At the conference, Yin Yong presented "service packages" to the heads of key pharmaceutical companies, including Sino Biopharm. Sino Biopharm will leverage the innovative ecosystem and policy advantages of BioPark to build an innovative R&D platform focusing on three major directions: AI-empowered innovative drug R&D, next-generation transdermal drug delivery technology, and central nervous system and brain science, and accelerate the industrial application of cutting-edge innovative technologies. 

Source: Beijing Daily, etc.